Laminectomy
Conditions
Keywords
Laminectomy, Esmolol Infusion, Quality of recovery, beta-blockers, Pain management, Postoperative pain, Opioid requirements, Intraoperative esmolol infusion, Return to normal activities of daily living
Brief summary
The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication.
Detailed description
A common practice used to control autonomic responses during surgery is to administer beta-blockers intraoperatively. This practice has been shown to effectively blunt autonomic responses to intraoperative events. Several studies have shown that administration of beta-blockers can decrease intraoperative anesthetic requirements. Additionally, it has been demonstrated in several studies that intraoperative beta-blocker administration may actually decrease postoperative pain scores and opioid requirements, although these results are not entirely consistent. The mechanism by which the decrease in postoperative pain and narcotic requirements occurs is unclear. It has been postulated that esmolol may itself possess some analgesic-like properties, as was suggested by studies performed in rodent models. It has also been postulated that perioperative beta-blockade may attenuate the neuroendocrine stress response to surgery, thereby decreasing inflammatory responses in tissues; however, this theory was not supported by a study in which stress hormone levels were measured in patients who received beta-blockers and compared to a control group. Several studies which investigated the effects of beta-blockade on postoperative pain and opioid requirements compared the beta-blocker treatment group to an opioid treatment group, and did not include a true control group in which no treatment was given. Therefore, it is unclear whether the decrease in postoperative pain and opioid requirements in these studies was due to a true effect of the beta-blockers or whether it was due to an effect of the opioids. Therefore, the investigators propose a randomized, double-blinded, placebo-controlled study in which the investigators will compare an esmolol infusion treatment group to a normal saline infusion control group with regards to the effects on postoperative pain and opioid requirements. By setting up the study in this manner, the investigators will be able to clearly evaluate the effects of beta-blockers on postoperative pain scores and opioid requirements. The investigators chose to use esmolol both because it has a short half-life, so it is easy to titrate and administer as an infusion, and also because it is selective for beta-1 receptors, so deleterious effects of intraoperative hypotension should be minimized. The investigators chose to perform the study on patients who are undergoing single-level or double-level laminectomies because prior studies have investigated the effects of intraoperative beta-blockers on patients who are not chronic pain patients, and the investigators would like to research whether the results which have been suggested by prior studies are also applicable to patients who may have chronic pain, as this is the patients population that is most likely to experience high pain levels following surgery, and may benefit the most from reduction of postoperative pain levels.
Interventions
DRUGEsmolol
Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
DRUGSaline
Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
Sponsors
Cedars-Sinai Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients scheduled to undergo single-level or double-level laminectomy under general anesthesia * Willingness and ability to sign an informed consent document * No allergies to any of the anesthetic or analgesic medications being used for the study, as outlined in the study protocol * Between 18-80 years of age * American Society of Anesthesiologists (ASA) class I-III adults of either sex
Exclusion criteria
* Patients who are ASA class IV or higher * Patients with known allergy, hypersensitivity, or contraindication to the use of any of the medications being used for the study, as outlined in the study protocol * Patients who are heavy chronic opioid users, defined for the purposes of this study as any patient who is taking the equivalent of 10mg of oral morphine per day or greater * Pregnant or lactating women * Patients with a history of drug or alcohol abuse within the past 3 months * Patients with any other medical conditions or who are using any medications which may interfere with the conduct of the study (including patients taking clonidine, patients with EKG conduction defects and who are taking calcium channel blockers, patients with clinically significant congestive heart failure (CHF) or bronchospasm, or patients with second- or third-degree heart block, symptomatic sinus bradyarrhythmia, or nonsinus rhythm on preoperative EKG.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-operative Pain Using Verbal Rating Scale (VRS) | 1 day | Verbal Rating Scale goes from 0 to 10, where: 0 indicates= No pain and 10 indicates= The worst possible pain The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Opioid Consumption in PACU Obtained From the Recorded Data | 1 day | Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts). |
| Postoperative Nausea and Vomiting | 1 day | Number of participants that experienced Postoperative nausea and vomiting using at PACU |
Countries
United States
Participant flow
Recruitment details
Prior to the day of surgery, potential study patients scheduled to undergo spine surgical procedures received a packet of materials from their surgeon. The packet contained an initial patient contact letter, a privacy information sheet, and the institution review board (IRB)-approved informed consent form.
Participants by arm
| Arm | Count |
|---|---|
| Placebo A normal saline bolus during induction, and an infusion of normal saline intraoperatively. | 17 |
| Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively | 16 |
| Total | 33 |
Baseline characteristics
| Characteristic | Placebo | Esmolol | Total |
|---|---|---|---|
| Age, Continuous | 59 years STANDARD_DEVIATION 11 | 54 years STANDARD_DEVIATION 16 | 57 years STANDARD_DEVIATION 14 |
| Body Mass Index (BMI) | 26 kg/m^2 STANDARD_DEVIATION 5 | 26 kg/m^2 STANDARD_DEVIATION 4 | 26 kg/m^2 STANDARD_DEVIATION 5 |
| Region of Enrollment United States | 17 participants | 16 participants | 33 participants |
| Sex: Female, Male Female | 8 Participants | 7 Participants | 15 Participants |
| Sex: Female, Male Male | 9 Participants | 9 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 17 | 0 / 16 |
| serious Total, serious adverse events | 0 / 17 | 0 / 16 |
Outcome results
Primary
Post-operative Pain Using Verbal Rating Scale (VRS)
Verbal Rating Scale goes from 0 to 10, where: 0 indicates= No pain and 10 indicates= The worst possible pain The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay
Time frame: 1 day
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Post-operative Pain Using Verbal Rating Scale (VRS) | 4 Scores on a scale | Standard Deviation 4 |
| Esmolol | Post-operative Pain Using Verbal Rating Scale (VRS) | 5 Scores on a scale | Standard Deviation 3 |
Secondary
Opioid Consumption in PACU Obtained From the Recorded Data
Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts).
Time frame: 1 day
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Opioid Consumption in PACU Obtained From the Recorded Data | 1.5 mg | Standard Deviation 0.6 |
| Esmolol | Opioid Consumption in PACU Obtained From the Recorded Data | 2 mg | Standard Deviation 2.6 |
Secondary
Postoperative Nausea and Vomiting
Number of participants that experienced Postoperative nausea and vomiting using at PACU
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Postoperative Nausea and Vomiting | 2 participants |
| Esmolol | Postoperative Nausea and Vomiting | 0 participants |